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Abstract
Background: Skin cancer accounts for 1/3 of all newly diagnosed cancer. Although seldom fatal,
basal cell carcinoma (BCC) is associated with severe disfigurement and morbidity. BCC has a
unique interest for researchers, as although it is often locally invasive, it rarely metastasises. This
paper, reporting the first whole genome expression microarray analysis of skin cancer, aimed to
investigate the molecular profile of BCC in comparison to non-cancerous skin biopsies. RNA from
BCC and normal skin specimens was analysed using Affymetrix whole genome microarrays. A
Welch t-test was applied to data normalised using dCHIP to identify significant differentially-
expressed genes between BCC and normal specimens. Principal component analysis and support
vector machine analysis were performed on resulting genelists, Genmapp was used to identify
pathways affected, and GOstat aided identification of areas of gene ontology more highly
represented on these lists than would be expected by chance.
Results: Following normalisation, specimens clustered into groups of BCC specimens and of
normal skin specimens. Of the 54,675 gene transcripts/variants analysed, 3,921 were differentially
expressed between BCC and normal skin specimens. Of these, 2,108 were significantly up-
regulated and 1,813 were statistically significantly down-regulated in BCCs.
Conclusion: Functional gene sets differentially expressed include those involved in transcription,
proliferation, cell motility, apoptosis and metabolism. As expected, members of the Wnt and
hedgehog pathways were found to be significantly different between BCC and normal specimens,
as were many previously undescribed changes in gene expression between normal and BCC
specimens, including basonuclin2 and mrp9. Quantitative-PCR analysis confirmed our microarray
results, identifying novel potential biomarkers for BCC.
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Background
It is estimated that the incidence of cutaneous basal cell
carcinoma is increasing worldwide by up to 10% per year
[1] and it currently accounts for approximately 80% of all
non-melanoma skin cancer – with highest rates in elderly
men and increasing incidence in young women [2]. Sev-
eral sub-types of BCC have been identified. These include
nodular-ulcerated BCC (the most frequently occurring
type; often with ulceration ("rodent ulcer")); superficial
BCC (often multiple); sclerosing BCC (cancer cells sur-
rounded by dense fibrosis and so resemble scars; highest
recurrence rate of BCCs after treatment); cystic BCC
(uncommon; tumour undergoes central degradation to
form a cystic lesion); linear BCC (recently recognised clin-
ical entity with increased risk for aggressive histopathol-
ogy); and micronodular BCC (small tumour nests; often
with subclinical growth). Although BCC only occasion-
ally (0.003–0.55% of cases [3-5]), results in metastasis
and is seldom fatal, BCC is often locally invasive with
destructive growth and may be associated with severe dis-
figurement and morbidity as a result of local tissue
destruction or due to necessary surgery. Furthermore, peo-
ple with BCC are at higher risks of developing further
BCCs and other malignancies, including squamous cell
carcinomas, malignant melanomas, and possibly also
non-cutaneous malignancies [1].
Current selection of best treatment for BCC is based on
accurate diagnosis and sub-classification of these cancers,
mainly on histomorphology/pathology of H&E stained
sections [6]. Features associated with recurrence and
metastasis are also considered – including tumour diame-
ter >2 cm, location in the central part of the face or ear,
present for long duration, incomplete excision, aggressive
growth pattern (based on histology) and perinuclear or
perivascular involvement [2]. Genes reported to be associ-
ated with susceptibility to BCC include CYP2D6, GST-T1,
vitamin D receptor, and TNF; with UVB irradiaton known
to cause mutations in the p53 tumour suppressor gene,
leading to the development of this cancer [1].
With the exception of a single study of BCCs using a small
cDNA microarray – representing 1,718 genes [7] – inves-
tigations aimed at identifying BCC biomarkers and under-
standing the molecular events involved in this disease
have, in general, been limited to one-at-a-time studies,
built on chance analyses of proteins or mRNAs. Examples
of such protein analysis have identified CD10 [8,9], p63
[10], low expression levels of CD44 [11] to be associated
with the presence of BCC, generally with absence of
ICAM-1 and LFA-3 adhesion molecule expression [12]
and with Ki67 expression levels differing between BCCs
that recur, compared to those that do not recur [13]. RT-
PCR analysis has indicated 1,25-dihydroxyvitamin D(3)
receptor mRNA levels to be increased in BCCs compared to
normal skin [14], while qPCR quantification of gli1 tran-
scripts has been found to discriminate BCC (and trichoep-
ithelioma) from other skin cancers [15].
While such studies have indicated the importance and rel-
evance of gene expression analyses in BCC, the number of
gene products simultaneously analysed have been very
limited. In order to increase our understanding of the
molecular events involved in the development/expression
of BCC, here we report our findings from whole genome
microarray analysis of BCC and normal skin specimens.
Results
Quality Control of Microarray Data
As indicated in Table 1, quality control (Q.C.) analysis of
all 25 microarray data sets (from 20 BCC and 5 normal
skin specimens) indicated an average percentage present
call of 42.68% (+/- 5.79 SD). This would be of the order
expected for high quality RNA from cell lines from many
origins (Affymetrix Inc. "Genechip® Expression Analysis
Data Analysis Fundamentals" [16], indicating that these
results are acceptable for further analysis. Again, based on
cell line Q.C. parameters, the accepted background levels
are <100, while 52.31 +/- 4.08 was found in this study;
acceptable noise levels are <3, here we report 1.67 +/- 0.4;
and the acceptable scaling factor is <3 fold between data
sets being compared. This was generally, but not always,
achieved. The acceptable 3'/M ratio of <3 was achieved in
18/25 cases.
Data Analysis
Approximately 7% (3,921/54,675) of the probe sets rep-
resenting transcripts on the microarray were significantly
differentially expressed between BCC and normal skin
specimens (Tables 2 &3; [see Additional Files 1 &2] for
further information). The scatter plot of data differentially
expressed ≥1.2 fold (Fig. 1) indicates an even, normal dis-
tribution of data. As shown in Table 4, of the 2,108 up-
regulated by ≥1.2 fold, genes involved in many crucial
aspects of cellular biology, including metabolism, tran-
scription, cell cycle regulation, cell adhesion, cell migra-
tion, cell proliferation and cell motility were amongst the
largest groups of genes affected, while oxidative phospho-
rylation, lipid metabolism, translation, and apoptosis
were among the main categories down-regulated ≥1.2 fold
in BCCs compared to normal skin (Table 5). Of the 748
probesets representing transcripts up-regulated by ≥2 fold,
approximately 11 were described as cloned cDNAs, 122
were ESTs, 6 were described as hypothetical genes, and 46
encoded hypothetical proteins. Of the 484 transcripts
showing  ≥2 fold down-regulation, twenty-five repre-
sented hypothetical proteins, 11 cloned cDNAs/RIKENS
and 49 ESTs.Molecular Cancer 2006, 5:74 http://www.molecular-cancer.com/content/5/1/74
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In order to identify specimen similarity/diversity in our
group of 25 skin specimens, condition tree clustering
(using Pearson's correlation coefficient as similarity met-
ric) and principal component analysis (PCA) were per-
formed using GeneSpring software. As indicated in Fig.
2(A), while Pearson's correlation coefficient does not sug-
gest a significant difference (i.e. no values <0.9) between
the 25 specimens analysed, the 5 normal specimens form
a discrete cluster in relation to the BCC specimens. (A sim-
ilar clustering pattern was obtained when Spearman's cor-
relation coefficient was investigated). Two of the BCC
specimens, T19 and T22, are apparently different (but not
significantly different) to the other 18 BCCs. While the 3'/
M ratios were greater than expected (at least in compari-
son to cell line data) for these specimens, this was also the
case for BCC26, T16, T24, T25 and T28, which did not
group with T19 and T22. The higher scaling factor result-
ing from analysis of T19 and T22, compared to all other
specimens, may be responsible for/contribute to their
apparently somewhat different behaviour as represented
on the condition tree. For the purpose of investigating the
effects of T19 and T22 on the overall dataset, a re-analysis
was performed excluding data relating to those speci-
mens. This resulted in a reduction from 3,921 (i.e. 7.17%)
to 3,865 (7.06%) of significantly differentially expressed
transcripts between BCC and normal specimens, indicat-
ing that the vast majority of these transcripts are unbiased
by the slightly different behaviour of T19 and T22 com-
pared to all other BCCs (as described above).
To further identify the relatedness of the BCC samples to
each other, we performed principal components analysis
[17] on the entire data set. PCA was carried out on log-
transformed data, using mean centering and scaling. As
can be seen in Fig. 2(B), while our PCA analysis has
divided the specimens into two groups, the results indi-
cate that the BCC sub-group is much more varied than the
normal skin group and that the BCC and normal skin
specimens do not differ greatly.
Support Vector Machine analysis [18] is a machine learn-
ing classification approach which is suitable for applica-
tion to the dimensionality of microarray data. It operates
by examining the expression information of a set of data
points whose classification is known (referred to as the
"training set"), from which a defined number of classifica-
tion predictor genes are identified. This predictor genelist
can then be applied to a separate set of genes which are
known not to be members of the functional class (referred
to as the "test set"). The predictor genelist is user-defined,
so it is more beneficial to the user for validation if a
smaller number of genes comprise the predictor list.
Table 1: Q.C. Analysis of Microarray Results
Specimen I.D. Present Call (%) Background Noise Scaling Factor 3'/M Ratio GAPDH
BCC26 49.9 52.6 1.82 0.94 14.56
JT2 50.2 63.6 2.05 0.795 1.41
JT3 49.9 53.85 1.74 1.037 1.27
BCC4 48.8 55.72 1.87 0.868 1.82
JT6 41.8 50.33 1.56 2.431 2.46
JT11 39 48.93 1.58 3.173 2.17
JT8 43 46.94 1.48 2.463 1.95
JT9 46.5 53.85 1.71 1.434 1.66
T16 43.4 51.87 1.62 1.896 3.25
JT12 38.1 53.09 1.7 2.709 2.86
JT13 47.1 54.46 1.67 1.374 1.67
JT4 46.5 55.73 1.77 1.18 1.66
JT5 45.8 53.86 1.75 1.453 1.86
T24 38.5 57.3 1.83 2.905 3.0
T25 34.1 56.57 1.77 3.988 3.1
T28 34.3 56.32 1.79 3.771 3.6
JT7 39.6 48.25 1.56 3.098 2.52
T11 43.3 50.10 1.61 2.416 2.1
T19 32.2 54.24 1.7 4.539 3.1
T22 29.1 49.14 1.59 6.639 5.86
N1 46.6 46.38 1.46 1.571 1.67
N2 44.0 47.85 1.56 1.565 1.8
N3 42.5 50.84 1.63 2.105 2.46
N5 46.7 48.96 1.54 1.417 1.85
N6 46.2 46.92 1.44 1.821 2.39
Note: Acceptable Q.C. cut-offs, based on high quality cell line RNA analysis, for background is <100; noise <3; scaling factor <3 fold between 
specimens being compared; 3'/M ratio <3 (Affymetrix Inc. "Genechip® Expression Analysis Data Analysis Fundamentals" [16]).Molecular Cancer 2006, 5:74 http://www.molecular-cancer.com/content/5/1/74
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Table 2: Gene Transcripts significantly up-regulated in BCC compared to normal skin specimens (≥1.2 fold; ≥100; p < 0.05).
probe set gene Accession fold change Difference P value
204697_s_at chromogranin A (parathyroid secretory protein 1) NM_001275 130.34 2497.11 0.000001
224590_at X (inactive)-specific transcript BE644917 69.08 427.18 0.001884
214218_s_at X (inactive)-specific transcript AV699347 62.79 621.31 0.00072
242964_at gb:AI421677/DB_XREF=gi:4267608/DB_XREF=tf54a03.x1/CLONE AI421677 55.54 730.97 0.000005
224588_at X (inactive)-specific transcript AA167449 49.82 2086.08 0.000552
204913_s_at SRY (sex determining region Y)-box 11 AI360875 27.92 228.19 0.000224
1560652_at gb:AL832136.1/DB_XREF=gi:21732679/TID=Hs2.407141.1/CNT=4 AL832136 26.21 638.38 0.000015
236029_at FAT tumor suppressor homolog 3 (Drosophila) AI283093 24.03 916.82 0.000015
214913_at a disintegrin-like and metalloprotease (reprolysin type) AB002364 23.97 605.9 0.000002
220345_at leucine rich repeat transmembrane neuronal 4 NM_024993 22.24 270.15 0.0061
233622_x_at Transcribed locus, weakly similar to XP_375099.1 hypothetical protein AL162077 21.31 105.45 0.005425
230863_at gb:R73030/DB_XREF=gi:847062/DB_XREF=yj94c11.s1/CLONE= R73030 20.05 292.94 0.029359
204915_s_at SRY (sex determining region Y)-box 11 AB028641 19.64 524.92 0.000059
204424_s_at LIM domain only 3 (rhombotin-like 2) AL050152 19.19 1287.59 0.003562
236407_at gb:R73518/DB_XREF=gi:847550/DB_XREF=yj93h12.s1/CLONE= R73518 18.1 355.25 0.000003
208025_s_at high mobility group AT-hook 2///high mobility group AT-hook 2 NM_003483 17.76 506.18 0.000173
215311_at MRNA full length insert cDNA clone EUROIMAGE 21920 AL109696 17.1 448.46 0.000013
227671_at X (inactive)-specific transcript AV646597 16.98 383.7 0.003059
218638_s_at spondin 2, extracellular matrix protein NM_012445 16.91 2992.93 0
208212_s_at anaplastic lymphoma kinase (Ki-1) NM_004304 16.76 835.41 0.000003
226346_at gb:AA527151/DB_XREF=gi:2269220/DB_XREF=ni07b08.s1/CLONE AA527151 15.34 534.55 0
204914_s_at SRY (sex determining region Y)-box 11 AW157202 15.1 310.64 0.000124
215443_at thyroid stimulating hormone receptor BE740743 14.95 239.99 0.00019
240460_at gb:AI190616/DB_XREF=gi:3741825/DB_XREF=qd38e02.x1/CLONE AI190616 14.91 168.09 0.000564
1562107_at hypothetical protein MGC14738 BC007100 14.73 284.47 0.000263
213960_at CDNA FLJ37610 fis, clone BRCOC2011398 T87225 14.18 534.88 0.000001
1565936_a_a
t
LIM domain only 3 (rhombotin-like 2) T24091 13.94 162.48 0.001811
229523_at gb:N66694/DB_XREF=gi:1218819/DB_XREF=yy71g08.s1/CLONE= N66694 13.82 614.51 0.000001
210055_at thyroid stimulating hormone receptor BE045816 13.81 181.7 0.000595
224646_x_at gb:BF569051/DB_XREF=gi:11642431/DB_XREF=602184410T1/ BF569051 13.81 1024.01 0.000261
207468_s_at secreted frizzled-related protein 5 NM_003015 13.54 437.41 0.001339
220518_at target of Nesh-SH3 NM_024801 13.44 448.75 0.001398
224997_x_at H19, imprinted maternally expressed untranslated mRNA AL575306 13.39 1131.86 0.000494
222940_at sulfotransferase family 1E, estrogen-preferring, member 1 U55764 13.29 560.15 0.000001
235795_at gb:AW088232/DB_XREF=gi:6044037/DB_XREF=xc99c09.x1 AW088232 13.26 199.49 0.000451
220090_at chromosome 1 open reading frame 10 NM_016190 12.79 736.69 0.00414
238584_at IQ motif containing with AAA domain W52934 12.68 222.06 0.001169
203878_s_at matrix metalloproteinase 11 (stromelysin 3) NM_005940 12.23 685.83 0.000417
1557215_at Transcribed locus, weakly similar to XP_375935.1 hypothetical protein AK056212 11.92 262.54 0.003503
210292_s_at protocadherin 11 Y-linked///protocadherin 11 X-linked AF332218 11.83 211.94 0.000324
1558964_at FAT tumor suppressor homolog 3 (Drosophila) AA334950 11.22 280.34 0.000123
214451_at transcription factor AP-2 beta (activating enhancer binding protein 2 NM_003221 10.67 2196.21 0
209816_at patched homolog (Drosophila) AL044175 10.59 245.97 0.001175
241617_x_at gb:BE961949/DB_XREF=gi:11764352/DB_XREF=601655369R1 BE961949 10.43 1011 0.000972
209815_at Patched homolog (Drosophila) BG054916 10.34 2145.95 0.000007
230496_at Hypothetical protein FLJ25477 BE046923 10.34 131.12 0.000467
205372_at pleiomorphic adenoma gene 1 NM_002655 10.1 1069.14 0
229942_at gb:AW024890/DB_XREF=gi:5878420/DB_XREF=wu92c11.x1 AW024890 9.98 1649.01 0
214297_at gb:BE857703/DB_XREF=gi:10371993/DB_XREF=7g46a02.x1 BE857703 9.86 819.59 0.000003
229669_at Hypothetical protein LOC339260 AA166965 9.83 237.59 0.001318
Top 50 transcripts – based on fold difference are shown (complete list is supplied as supplementary material).Molecular Cancer 2006, 5:74 http://www.molecular-cancer.com/content/5/1/74
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Table 3: Gene Transcripts significantly down-regulated in BCC compared to normal skin specimens (≥1.2 fold; ≥100; p < 0.05).
probe set gene Accession fold 
change
Difference P value
239929_at hypothetical protein FLJ32569 AA918425 -28.24 -3433.29 0.014118
208962_s_at fatty acid desaturase 1 BE540552 -20.2 -3188.7 0.045399
229476_s_at thyroid hormone responsive (SPOT14 homolog, rat) AW272342 -17.15 -4660.08 0.034919
207275_s_at acyl-CoA synthetase long-chain family member 1 NM_001995 -15.11 -1865.7 0.039975
206799_at secretoglobin, family 1D, member 2 NM_006551 -14.97 -1291.31 0.042413
234513_at elongation of very long chain fatty acids (FEN1/Elo2, SUR4/Elo3, yeast)-like AF292387 -13.28 -670.81 0.022544
221561_at sterol O-acyltransferase (acyl-Coenzyme A: cholesterol acyltransferase) 1 L21934 -12.23 -998.57 0.008422
206714_at arachidonate 15-lipoxygenase, second type NM_001141 -11.45 -3891.76 0.045644
214240_at galanin AL556409 -11.12 -1590.25 0.015802
244661_at gb:AA946876/DB_XREF=gi:3110271/DB_XREF=oq53c11.s1/CLONE= AA946876 -10.56 -399.74 0.017168
244780_at sphingosine-1-phosphate phosphotase 2 AI800110 -9.79 -351.6 0.024348
201625_s_at insulin induced gene 1 BE300521 -9.72 -1591.34 0.030044
231810_at BRI3 binding protein BG106919 -8.9 -877.2 0.021503
1565162_s_at microsomal glutathione S-transferase 1 D16947 -8.6 -1071.37 0.030259
238121_at Transcribed locus, weakly similar to XP_341569.1 similar to ORF4 AI473796 -8.29 -445.99 0.042733
211056_s_at steroid-5-alpha-reductase, alpha polypeptide 1 (3-oxo-5 alpha-steroid delta BC006373 -7.88 -1432.56 0.032165
229957_at Branched chain keto acid dehydrogenase E1, alpha polypeptide BF446281 -7.63 -1214.3 0.025272
204675_at steroid-5-alpha-reductase, alpha polypeptide 1 (3-oxo-5 alpha-steroid delta NM_001047 -7.35 -2832.7 0.027894
233030_at adiponutrin AK025665 -7.35 -1220.35 0.031698
231736_x_at microsomal glutathione S-transferase 1 NM_020300 -7.28 -2497.22 0.031804
205029_s_at fatty acid binding protein 7, brain NM_001446 -7.24 -524.52 0.021739
201627_s_at insulin induced gene 1 NM_005542 -7.23 -627.89 0.049971
209522_s_at carnitine acetyltransferase BC000723 -7.23 -2039.08 0.020824
226064_s_at diacylglycerol O-acyltransferase homolog 2 (mouse) AW469523 -7.1 -2291.54 0.032748
231156_at gb:AW242782/DB_XREF=gi:6576459/DB_XREF=xm89g06.x1/CLONE AW242782 -7.09 -339.26 0.045195
223184_s_at 1-acylglycerol-3-phosphate O-acyltransferase 3 BC004219 -7.01 -1374.94 0.045149
232428_at monoacylglycerol O-acyltransferase 2 AK000245 -6.97 -182.68 0.038707
1558846_at Pancreatic lipase-related protein 3 AL833418 -6.71 -2007.72 0.044402
205030_at fatty acid binding protein 7, brain NM_001446 -6.41 -1864.48 0.021392
205843_x_at carnitine acetyltransferase NM_000755 -6.41 -1166.98 0.020573
224435_at chromosome 10 open reading frame 58///chromosome 10 open reading BC005871 -6.37 -1905.14 0.007356
1560507_at Diacylglycerol O-acyltransferase 2-like 3 BC039181 -6.28 -441.54 0.028259
215726_s_at cytochrome b-5 M22976 -5.95 -3458.82 0.02416
220431_at DESC1 protein NM_014058 -5.94 -112.38 0.029175
225716_at gb:AI357639/DB_XREF=gi:4109260/DB_XREF=qy15b05.x1/CLONE= AI357639 -5.94 -1718.34 0.01598
204388_s_at monoamine oxidase A NM_000240 -5.89 -362.75 0.037779
45288_at abhydrolase domain containing 6 AA209239 -5.83 -698.25 0.020361
218804_at transmembrane protein 16A NM_018043 -5.75 -234.79 0.045057
228479_at gb:AI094180/DB_XREF=gi:3433156/DB_XREF=qa29b09.s1/CLONE= AI094180 -5.7 -1191.04 0.029615
227804_at hypothetical protein BC014072 BE328850 -5.62 -363.64 0.043913
234312_s_at acetyl-Coenzyme A synthetase 2 (ADP forming) AK000162 -5.54 -1297.68 0.044265
1562528_at RAR-related orphan receptor A BC040965 -5.48 -120.02 0.025055
208964_s_at fatty acid desaturase 1 AL512760 -5.46 -3305.87 0.025757
213693_s_at gb:AI610869/DB_XREF=gi:4620036/DB_XREF=tp21e08.x1/CLONE= AI610869 -5.43 -1427.55 0.023253
237507_at keratin 6 irs3 AI333069 -5.43 -271.6 0.008082
204389_at monoamine oxidase A NM_000240 -5.4 -180.28 0.0359
214598_at claudin 8 AL049977 -5.27 -370.2 0.01827
201963_at acyl-CoA synthetase long-chain family member 1 NM_021122 -5.19 -4459.79 0.010049
218434_s_at acetoacetyl-CoA synthetase NM_023928 -5.17 -1842.1 0.004574
221552_at abhydrolase domain containing 6 BC001698 -5.06 -402.38 0.024809
Top 50 transcripts – based on fold difference are shown (complete list is supplied as supplementary material).Molecular Cancer 2006, 5:74 http://www.molecular-cancer.com/content/5/1/74
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Table 4: GOstat analysis of biological processes.
GO Number Observed Transcripts Total Transcripts GO Category P value
GO:0019222 293 3309 regulation of metabolism 1.24E-33
GO:0006351 264 2884 transcription, DNA-dependent 5.41E-33
GO:0006355 258 2809 regulation of transcription, DNA-dependent 1.61E-32
GO:0006357 55 280 regulation of transcription from RNA polymerase II promoter 5.40E-31
GO:0008134 57 346 transcription factor binding 6.86E-24
GO:0016563 45 250 transcriptional activator activity 9.36E-22
GO:0003677 240 2906 DNA binding 1.54E-21
GO:0003712 44 276 transcription cofactor activity 3.54E-17
GO:0007049 89 807 cell cycle 9.89E-17
GO:0016043 163 1986 cell organization and biogenesis 8.78E-14
GO:0003713 30 171 transcription coactivator activity 1.08E-13
GO:0008283 65 560 cell proliferation 1.17E-13
GO:0051726 61 522 regulation of cell cycle 5.62E-13
GO:0000074 60 518 regulation of progression through cell cycle 1.51E-12
GO:0005578 48 377 extracellular matrix 3.00E-12
GO:0007155 77 874 cell adhesion 5.65E-08
GO:0008380 24 173 RNA splicing 3.60E-07
GO:0016477 18 112 cell migration 5.56E-07
GO:0016055 19 128 Wnt receptor signaling pathway 2.09E-06
GO:0008219 60 675 cell death 2.29E-06
GO:0007167 25 207 enzyme linked receptor protein signaling pathway 1.13E-05
GO:0030154 50 550 cell differentiation 1.13E-05
GO:0005604 13 62 basement membrane 7.37E-05
GO:0051301 22 190 cell division 0.000156
GO:0042981 38 418 regulation of apoptosis 0.000269
GO:0000904 11 66 cellular morphogenesis during differentiation 0.00262
GO:0043123 13 91 positive regulation of I-kappaB kinase/NF-kappaB cascade 0.00344
GO:0005581 11 73 collagen 0.00597
GO:0030198 8 43 extracellular matrix organization and biogenesis 0.00788
GO:0007154 247 4475 cell communication 0.0122
GO:0005583 4 11 fibrillar collagen 0.0125
GO:0008286 5 20 insulin receptor signaling pathway 0.0182
GO:0016049 17 174 cell growth 0.019
GO:0008361 17 174 regulation of cell size 0.019
GO:0005610 2 2 laminin-5 0.0205
GO:0008083 20 221 growth factor activity 0.0232
GO:0005588 2 3 collagen type V 0.0477
Biological processes that are significantly enriched in our set of 2,108 transcripts found to be significantly up-regulated in BCC compared to normal 
skin specimens. Shown here is a sub-set of 37 representative significant GO annotations.Molecular Cancer 2006, 5:74 http://www.molecular-cancer.com/content/5/1/74
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For the purposes of this study, we carried out SVM analysis
repeatedly on the tumour vs. normal dataset, in order to
identify the lowest number of probesets that discrimi-
nated 100% of the time between the two classifications.
The gene selection method used was Fisher's Exact Test,
the kernel function was Polynomial Dot Product (Order
1) with zero Diagonal Scaling Factor. A minimum
number of six identifiers, shown in Table 6, were required
for 100% classification of every specimen as either
tumour or normal in origin. Attempts to further prioritise
these genes resulted in a decrease in the efficiency of the
classification, as further analysis aimed at classifying the
specimens using less than six transcripts resulted in the
mis-classification of normal specimen N5 as a BCC speci-
men.
qPCR Validation of Microarray Data
Quantitative-PCR (qPCR) analysis for 10 potential endog-
enous controls was performed on a random selection of
four BCC and four normal skin specimens, to select a suit-
able endogenous control(s) amplifiable in all specimens
and where levels of expression did not differ greatly
between specimens being analysed. All 10 transcripts
studied were found to be expressed in all specimens ana-
lysed and, as indicated in Fig. 3 [Additional File 3], expres-
sion levels and standard deviation results suggested that
Table 5: GOstat analysis of biological processes.
GO Number Observed Transcripts Total Transcripts GO Category P value
GO:0006119 36 138 oxidative phosphorylation 2.77E-34
GO:0006091 120 1003 generation of precursor 
metabolites and energy
3.75E-33
GO:0016491 123 1170 oxidoreductase activity 7.47E-26
GO:0006732 44 269 coenzyme metabolism 5.71E-21
GO:0006629 86 765 lipid metabolism 1.17E-20
GO:0003954 24 62 NADH dehydrogenase 
activity
8.07E-16
GO:0043037 40 280 translation 4.26E-15
GO:0016651 27 99 oxidoreductase activity, 
acting on NADH or 
NADPH
1.63E-13
GO:0016126 16 31 sterol biosynthesis 5.82E-13
GO:0008135 29 185 translation factor activity, 
nucleic acid binding
8.99E-13
GO:0045045 30 217 secretory pathway 1.31E-10
GO:0006099 14 45 tricarboxylic acid cycle 5.49E-08
GO:0046356 14 45 acetyl-CoA catabolism 5.49E-08
GO:0006511 25 201 ubiquitin-dependent 
protein catabolism
2.83E-07
GO:0006413 17 84 translational initiation 1.20E-06
GO:0048193 19 108 Golgi vesicle transport 2.00E-06
GO:0006412 87 1228 protein biosynthesis 5.29E-06
GO:0008289 35 380 lipid binding 2.46E-05
GO:0006445 15 92 regulation of translation 7.85E-05
GO:0006888 13 72 ER to Golgi vesicle-
mediated transport
9.90E-05
GO:0006915 49 644 apoptosis 0.000214
GO:0008415 20 190 acyltransferase activity 0.000313
GO:0006944 7 32 membrane fusion 0.00289
GO:0016281 4 9 eukaryotic translation 
initiation factor 4F complex
0.00313
GO:0006984 4 9 ER-nuclear signaling 
pathway
0.00313
GO:0044242 7 33 cellular lipid catabolism 0.00349
GO:0030503 3 5 regulation of cell redox 
homeostasis
0.00611
GO:0007050 11 85 cell cycle arrest 0.00717
GO:0016282 5 27 eukaryotic 43S preinitiation 
complex
0.0303
Biological processes that are significantly enriched in our set of 1,813 transcripts found to be significantly down-regulated in BCC compared to 
normal skin specimens. Shown here is a sub-set of 29 representative significant GO annotations.Molecular Cancer 2006, 5:74 http://www.molecular-cancer.com/content/5/1/74
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the 10 transcripts are likely to be of similar suitability as
endogenous controls. Two controls, β-actin and GAPDH,
were subsequently selected for amplification in all speci-
mens, in parallel with a selection of 5 target transcripts of
interest. The relative expression levels of PTCH1, gli2, Friz-
zled D2, basonuclin 2, and chromagranin A were analysed by
qPCR. As indicated in Table 7, while the fold differences
detected by microarray and qPCR methods differed to
some extent, the trend (i.e. absent/low expression in nor-
mal skin and induced/increased expression in BCCs) was
always found.
Discussion
Basal cell carcinoma (BCC), the most common skin can-
cer in humans, is locally aggressive and relentlessly inva-
sive, but generally does not metastasise [5,19]. Despite
this, studies aimed at investigating the molecular mecha-
nisms associated with – possibly responsible for – BCCs,
have been very limited. In 2005, Howell et al. [7] reported
findings from their analysis of 1,718 transcripts in BCC
specimens, using cDNA microarrays. While this study pro-
duced very interesting results, as explained by the authors,
numbers of transcripts potentially important in BCC –
such as PTCH1 and SMO – were not represented on their
microarray; limiting their study considerably. Here we
have successfully analysed gene expression of BCCs, com-
pared to normal skin, using whole genome microarrays
and following extensive analysis of our data, in addition
to confirming previous findings, we have identified a
number of novel potential biomarkers/therapeutic targets
for this disease.
Comparison of our results with those generated by How-
ell et al. [7] indicated a relatively high level of agreement
between these two studies. Many of the transcripts identi-
fied by Howell et al. as up-regulated in BCC compared to
normal skin were also found to be up-regulated in BCC in
our study. Examples of these include collagens (type V,
alpha 1 & alpha 2; type IV alpha 1 & 2; type VII alpha 1),
topoisomerase IIα,  tumour-associated calcium signal trans-
ducer 1, profilin 2, calretinin, syndecan 2, and v-myc. Simi-
larly, a high concordance between these two studies was
found for transcripts down-regulated in BCCs compared
to normal specimens; examples of which include cystatin
B, acetyl-Coenzyme acyltransferase 1, 3-hydroxy-3-methylglu-
taryl-Coenzyme A reductase, glutaredoxin, amyloid β (A4) pre-
cursor-like protein, and cytochrome b-5. However, in the case
of a limited number of differentially expressed transcripts,
the direction of change in expression in BCC compared to
normal skin was not in agreement. Examples include
ADP-ribosylation factor 3 (down-regulated by 1.67 fold in
our study [expression values 941.51 vs. 563.45], but up-
regulation reported by Howell et al. [7] and glia maturation
factor β (1.42 up-regulated in our analysis [expression val-
ues 969.02 vs. 1,377.23], but reported by Howell et al. as
down-regulated). While the reasons for these limited
number of discrepencies is unknown, it may be due to dif-
ferent splice variants of these transcripts being detected by
cDNA compared to oligo microarrays. It is worth noting
that the results that differed between our study and that of
Howell et al. were generally transcripts that we found to be
<2 fold differentially expressed between BCC and normal
skin. Unfortunately, as fold changes observed by Howell
et al. [7] were not reported in their manuscript and infor-
mation is not publicly available on transcripts that were
present on their microarray, but were not significantly
changed, further comparisons between these studies can-
not be performed.
The development of BCC is known to be associated with
dys-regulation of the hedgehog and Wnt pathways [2,20].
Lack of expression and/or suppressed activation of
patched homologue 1 (PTCH1), a tumour suppressor
gene that forms part of the hedgehog signaling network
[21], has been reported to be fundamental to the develop-
ment of BCC [22]. Disruption of this tumour suppressor
gene results in up-regulated cell proliferation [6]. The
accepted mechanism of PTCH1's action is via its binding
to another transmembrane molecule, smoothed (SMO),
thus suppressing intracellular signaling. Following bind-
ing of sonic hedgehog (shh) to PTCH1, this suppressor
activity is, however, quenched, resulting in uninterrupted
signal transduction by SMO, via GLI transcription factors,
and subsequent constitutive activation of target genes,
Scatter Plot of the 3,921 gene transcripts identified as signifi- cantly differentially expressed (by ≥1.2 fold; ≥100 difference  in expression intensity; P < 0.05) between BCC and normal  skin specimens Figure 1
Scatter Plot of the 3,921 gene transcripts identified as signifi-
cantly differentially expressed (by ≥1.2 fold; ≥100 difference 
in expression intensity; P < 0.05) between BCC and normal 
skin specimens. Transcripts significantly up-regulated are 
shown in red; those down-regulated are shown as green.Molecular Cancer 2006, 5:74 http://www.molecular-cancer.com/content/5/1/74
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(A) Condition tree distribution of the 20 BCC (red) and 5 normal skin (yellow) specimens (following dCHIP normalisation, sim- ilarity measure, Pearson's correlation, clustering algorithm, average linkage) Figure 2
(A) Condition tree distribution of the 20 BCC (red) and 5 normal skin (yellow) specimens (following dCHIP normalisation, sim-
ilarity measure, Pearson's correlation, clustering algorithm, average linkage). Expression values ≥100 are indicated in red; ≥50 
to <100 are indicated in black, and 0 to <50 are indicated in green. (B) Two-dimensional principal component analysis (PCA) 
plot where red dots represent BCC specimens and yellow dots represent normal skin specimens indicating that while the nor-
mal specimens form a loose cluster (solid line oval), the BCC specimens are more "scattered" and varied (broken line oval). The 
first principal component expression value is 29.73%; the second component expression value is 12.05%.Molecular Cancer 2006, 5:74 http://www.molecular-cancer.com/content/5/1/74
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including members of the Wnt pathway [23] and PTCH1,
itself [21]. From our analysis of BCC compared to normal
skin tissue, while we found no significant changes in shh
expression levels, we report an approximately 11 fold
increased expression of PTCH1 [expression values 25.65
vs. 271.62], and also increased expression of gli2 (7.39
fold; P = 0.00009) [expression values 23.52 vs. 173.73],
respectively. The induced/increased expression of PTCH1
and gli2 found by microarray analysis was confirmed by
qPCR analysis of all specimens (see Table 7). It is impor-
tant to note that the likely reason for the difference in fold
expression detected by microarray and qPCR methods is
due to their differing baseline sensitivity. Low expression
levels detected by microarrays – e.g. gli2 in normal skin –
resulting in large fold differences are considered as induc-
tion from absent in normal skin compared to present in
BCC specimens, when analysed by qPCR. However,
although  PTCH1  mRNA levels have previously been
reported as enhanced in nodular BCC but undetectable in
superficial BCC [24], here we report PTCH1 to be detecta-
ble in both of these histological types of BCC, with no sig-
nificant difference in their respective expression values (t-
test: p = 0.637).
While the increased expression of gli2 detected in BCCs
compared to normal skin may be expected and associated
with the development/presence of BCC, the lack of
tumour suppressor activity by PTCH1 – despite its
increased mRNA levels – may be due to lack of expression
of its corresponding protein and/or lack of binding to
SMO  (levels of which were not significantly different
between BCC and normal skin). As PTCH1 may shuttle
between the cell membrane and endocytotic vesicles in
response to active hedgehog ligand, it is obvious that not
only its mRNA expression, but also its protein expression
(at the relevant location, binding of SMO, etc.) is neces-
sary to exert its tumour suppressor activity [21]. Further-
more, as loss-of-function mutations of PTCH1 have been
identified in 30–40% of sporadic cases of BCC, it may be
that the mRNA over-expressed in the BCCs is not coding
for a functional protein.
Wnt signaling may be able to regulate a number of the
aspects of the biology of tumour cells and thus contribute
in several ways to the tumour phenotypes. The strongest
link is to the control of proliferation. Knockouts of Wnt
signal transduction components, including Wnt5A, can
result in proliferative failure [25] while up-regulation of
Wnt5A mRNA expression been associated with a range of
cancer types, including breast, lung, prostate and malig-
nant melanomas [26,27]. In our study, the involvement
of Wnt signaling pathway in BCC is suggested by the sig-
nificantly increased expression of a number of Wnt family
members. These include Wnt5A (3.35 fold; P = 0.00003)
[expression values 403.73 vs. 1,353.71], – in agreement
with a study by Saldanha et al. [19] where Wnt5A levels
were increased in BCCs compared to surrounding skin –
and Wnt6 (4.86 fold; P = 0.00002) [expression values 59.7
vs. 290.26]. Increased levels of Wnt ligand binding recep-
tors, Frizzled D2 (8.94 fold; P = 0.000033) [expression val-
Table 7: Validation of microarray data by qPCR
Transcript I.D. Microarray1 Mean 
Expression Levels in 
Normal Skin
Microarray1 
Mean Expression 
Levels in BCC
Microarray 
(fold)2
qPCR3 Mean 
Expression Levels 
in Normal Skin
qPCR3 Mean 
Expression 
Levels in BCC
qPCR 
(fold)2
chromagranin A NM_001275 19.31 2516.41 130.34 0.000 1.083 P
gli2 NM_030379 23.51 173.73 7.39 0.000 1.662 P
PTCH1 BG054916 229.86 2375.81 10.34 0.025 1.455 58.2
basonuclin 2 NM_017637 204.42 1827.2 8.94 0.077 1.034 13.4
frizzled 2 L37882 54.93 490.8 8.94 0.047 6.505 138.4
Note: 1 = Expression levels, Affymetrix arbitrary units; 2 = fold increased expression in BCC compared to normal; 3 = following normalisation of data 
on mean of β-actin + GAPDH expression and calibrating to a pooled skin specimen control (as described in Materials and Methods); P = induced in 
BCC, while undetected in normal skin
Table 6: Transcripts identified using Support Vector Machine as suitable, as a group, for 100% classification of BCC from normal skin.
I.D. Gene Transcript
1553718_at zinc finger protein 548
201413_at hydroxysteroid (17-beta) dehydrogenase 4
225677_at B-cell receptor-associated protein 29
223184_s_at 1-acylglycerol-3-phosphate O-acyltransferase 3
203878_s_at matrix metalloproteinase 11 (stromelysin 3)
225716_at Full-length cDNA clone CS0DK008YI09 of HeLa cells Cot 25-normalized of Homo sapiens (human)Molecular Cancer 2006, 5:74 http://www.molecular-cancer.com/content/5/1/74
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ues 54.93 vs. 490.8], D7  (2.31 fold; P = 0.000085)
[expression values 276.23 vs. 638.34], and D8 (5.89 fold;
P = 0.000055) [expression values 44.44 vs. 261.74], and
decreased levels of D4 (-2.78 fold; P = 0.02) [expression
values 598.41 vs. 215.2], were also found. The increased
expression of Frizzled D2 in BCC compared to normal skin
was confirmed by qPCR.
In the "canonical" Wnt signaling pathway, secreted lig-
ands bind to Frizzled receptors and regulate the stability
of β-catenin. (Given the large number of mammalian Friz-
zleds and Wnts, considerable ligand-receptor specificity
might be expected; however, redundancy of function
seems to be the rule [25]). The subsequent accumulation
of β-catenin – the central player in the Wnt pathway [28]
– in the nucleus, results in its participation in transcrip-
tionally active complexes with members of the LEF/TCF
family of transcription factors [29]. While we did not find
levels of β-catenin to be significantly different between
BCC and normal skin, decreased (-2.1 fold; P = 0.006)
[expression values 2,090.09 vs. 992.89], levels of
CTNNBIP1, an inhibitor of β-catenin and TCF-4 (ICAT)
which would normally prevent β-catenin binding to LEF
transcription factors [30-32] and increased levels of LEF1
transcripts (3.42 fold; P = 0.000001) [expression values
513.06 vs. 1,752.32], were found. Levels of Jun (2.34 fold;
P = 0.00006) [expression values 875.92 vs. 2,052.07],
another transcription factor involved in the Wnt pathway
[33], were also found to be increased in BCCs compared
to normal skin. Differential expression of other transcrip-
tion factors associated with cancer has also been found in
this study. These include CHES1 (checkpoint suppressor 1)
which is apparently involved in repressing expression of
genes important for tumorigenesis [34]. CHES1 mRNA
has been reported as down-regulated in oral squamous
cell carcinoma [35] and in hepatocellular carcinoma [36].
Here we found CHES1 mRNA levels to be significantly (-
2.03 fold; P = 0.045) [expression values 920.32 vs.
452.95], down-regulated in BCC compared to normal
skin. Not unexpectedly, mRNAs encoding proteins
involved in inducing apoptosis were also found to be
down-regulated. These include CIDE [37] and CARD15
[38] which are 4.18 fold (P = 0.029) [expression values
415.5 vs. 99.41] and 2.31 fold (P = 0.031) [expression val-
ues 313.08 vs. 135.42], down-regulated in BCC compared
to normal skin.
Using support vector machine analysis we have identified
6 transcripts that, as a group, enable the accurate classifi-
cation of all 25 specimens as BCC or normal skin. These
include  matrix metalloproteinase 11/mmp11 (previously
associated with the presence of other cancer types, includ-
ing oral [39,40], lung [41] and breast [42]); hydroxysteroid
(17-beta) dehydrogenase 4/hsd17b4 (changes in expression
of which have been associated with breast cancer ([43]);
B-cell receptor-associated protein 29/bap29 (a member of the
B cell receptor-associated family of proteins [44-46]); 1-
acylglycerol-3-phosphate O-acyltransferase 3/agpat3 (which
catalyses the acylation of lysophosphatidic acid to form
phosphatidic acid, the precursor of all glycerolipids [47]);
as well as zinc finger protein 548 and full-length cDNA clone
CS0DK008YI09 of HeLa cells Cot 25-normalized of homo
sapiens, on which no literature has previously been pub-
lished. Future studies involving the co-analysis of this
group of 6 transcripts in larger cohort of BCC and normal
skin specimens should enable validation of their diagnos-
tic relevance.
Molecular events responsible for the quite unique inva-
sive, but non-metastatic, nature of BCCs are not known.
However, it is interesting to note that expression of certain
genes believed to be involved in malignant invasion and
metastasis of another form of skin cancer, i.e. malignant
melanoma, apparently differ in their expression patterns
in BCCs. AP-2  transcription factor is not expressed in
malignant melanoma cells [48], but it is significantly up-
regulated (by 10.7 fold) [expression values 227.05 vs.
2,423.26], in BCC specimens compared to normal skin.
Conversely, increased expression of EGF-R is associated
with melanomas metastasis [48], but its expression is
down-regulated (by approximately 1.2 fold) [expression
values 76.91 vs. 62.78], in BCCs. Unlike BCCs, breast can-
cers frequently metastasise. Interestingly, in our microar-
ray study of 104 breast tumours and normal breast tissue
(manuscript in preparation) we identified changes in expres-
sion patterns of syndecan adhesion receptors (for review:
see [49]) i.e. syndecan 1 is up-regulated, and syndecan 2 is
down-regulated, in breast tumours compared to normal
breast tissue. In this study of non-metastatic BCCs, we
found syndecan 1 to be approximately 1.6 fold down-reg-
ulated [expression values 3,488.91 vs. 2,124.43], and syn-
decan 2 to be approximately 3 fold [expression values
160.21 vs. 559.84] up-regulated compared to levels in
normal skin tissue. Furthermore, ankyrin (encoding
membrane-associated cytoskeletal proteins) binding to
membrane molecules has been suggested as necessary for
cell adhesion, migration and tumour metastasis [50]. In
our breast cancer study we found ankyrin 3 expression lev-
els to be up-regulated compared to normal tissue, while
here we report ankyrin 3 levels to be down-regulated
(approximately 1.6 fold) [expression values 350.02 vs.
224.48], in BCC compared to normal tissue. While func-
tional studies would be required to determine a causative/
direct, rather than an associative, role for transcripts such
as AP-2, EGF-R, syndecan 1 &2, and ankyrin 3 in controlling
metastasis, the results from this study suggest that expres-
sion of the mRNAs may be, in some way, involved in this
process.Molecular Cancer 2006, 5:74 http://www.molecular-cancer.com/content/5/1/74
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Differential expression, between BCC and normal skin, of
many transcripts not previous associated with the pres-
ence of BCC was also found during the course of our
study. Basonuclin (now termed Basonuclin 1; was first
discovered in cultured human epidermal cells [51]) and
the more recently discovered basonuclin 2 [52] are zinc
finger proteins. Basonuclin 1 is expressed at high levels in
proliferating keratinocytes of stratified squamous epithe-
lium. During terminal differentiation of squamous epi-
thelium, basonuclin mRNA and protein disappear from the
suprabasal cells [53,54]. In normal cultured human kerat-
inocytes, basonuclin 1 is the predominant transcript – with
expression levels approximately 10 fold that of basonuclin
2 [52]. In this study we found that basonuclin 1 levels did
not differ significantly between BCC and normal skin,
although a previous study of 3 BCC and 2 normal skin
specimens indicated increased expression of basonuclin 1
in BCC, dependent on Gli protein expression [55]. In con-
trast, we report basonuclin 2 levels to be significantly
increased in BCCs. This finding was observed with all 4
basonuclin 2 probe sets present on the microarray, indicat-
ing a 6.7–9.6 fold increase level (P < 0.00005) of expres-
sion [greatest change in expression values being 85.63 vs.
828.01], in BCC. This increased expression of basonuclin 2
in BCC compared to normal skin was confirmed by qPCR
analysis. This, we believe, is the first study indicating an
association between expression of basonuclin 2 and BCC.
ABCC12/mrp9, identified in 2001 [56] is one of a super-
family of 9 ATP-binding cassette (ABC) multiple drug
resistant proteins [57]. Mrp9 encodes an approximately
100 kDa protein detectable in breast cancer, normal
breast tissue and testis, while an alternative mrp9 tran-
script – encoding an approximately 25 kDa protein – has
been detected in normal brain, skeletal muscle and ovary
tissues. Due to the differential levels of expression of mrp9
transcripts in breast tumour and normal tissue, MRP9 has
been proposed as an immunotherapy target for breast
cancer [58]. The functional relevance of our observation
of approximately 8.7 fold greater levels of mrp9 [expres-
sion values 21.12 vs. 184.71] in BCC compared to normal
skin has yet to be determined; its presence is unlikely to be
involvement in drug resistance, as all of the BCCs
included in this study were chemotherapy-naive (indeed,
except in a limited number of advanced cases of BCC,
chemotherapy is not used as a therapy for this disease. In
these exceptional cases, excellent response rates have been
reported with cisplatin in combination with either 5-
fluorouracil or doxorubicin [59]). However, as for breast
cancer, mrp9 mRNA may be useful as a member of a panel
of BCC biomarkers or as an immunotherapy.
Chromagranin A (ChgA; parathyroid secretory protein 1)
is an established tissue marker associated with neuroen-
docrine differentiation – and indicative of outcome – in
non-small cell lung carcinoma [60]. Increased levels of
ChgA in serum have been associated with poor prognosis/
shortened survival for prostate cancer patients [61]. ChgA
protein levels have been proposed to assist in the diagno-
sis of Merkel cell carcinoma patients who may benefit
from oncological therapy [62-64]. Although described as
relatively uncommon – using analysis of markers includ-
ing ChgA – neuroendocrine differentiation in BCC has
been reported [65]. In this study we have found ChgA lev-
els to be significantly (130.3 fold; P = 0.000001) [expres-
sion values 19.31 vs. 2,516.41], up-regulated in BCCs
compared to extremely low levels in normal skin speci-
mens. This is in agreement with the observation of ChgA
protein detectable in 55% (11/20) BCC specimens [66].
By qPCR analysis, ChgA was undetected in normal skin
but was present in BCC specimens. Interestingly, other
neuroendocrine markers, including SNAP-25 (3.24 fold; P
= 0.008) [expression values 40.17 vs. 130.25] and neu-
roendocrine protein 1/7B2 protein (3.48 fold; P = 0.0001)
[expression values 46.38 vs. 161.44], were also increased
in the BCC specimens. These results indicate ChgA to be a
potentially very useful marker for BCC.
In this study we present the first whole genome expression
microarray analysis of skin cancer, aimed at investigating
the molecular profile of BCC in comparison to non-can-
cerous skin biopsies. This investigation has not only con-
firmed previous findings from analyses of limited
numbers of transcripts, but it has also identified changes
in expression of mRNAs that had never previously been
associated with this disease. The results from this work are
interesting and exciting, but it is necessary to recognise
their preliminary nature. Further analyses, building on
our findings, should include independent replication
studies so that the true relevance of these findings may be
realised.
Conclusion
The success of this study indicates the feasibility and rele-
vance of using whole genome microarrays to study BCC
specimens. In addition to confirming previous findings,
this work has increased our understanding of molecular
differences between BCC and normal skin and has identi-
fied a number of novel potential biomarkers for BCC.
Future studies including BCC tissue and normal skin tis-
sue from the same individual, thus lowering inter-individ-
ual variability and ruling out genetic influences; analyses
of age- and gender-matched cases; studies focusing on
molecular profiling and comparisons of sub-types of BCC,
with due consideration given to disease duration (as early
tumours may have a different gene expression profile to
prolonged tumours); as well as analysing BCCs that
metastasise compared to those that do not, should further
increase our understanding of this disease and assist in
management of the individual BCC patients. Further-Molecular Cancer 2006, 5:74 http://www.molecular-cancer.com/content/5/1/74
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more, as gene expression may be independent of protein
levels, future confirmatory analysis at the protein level
would complement these findings.
Materials
Patient Characteristics
This study involved analysis of 20 BCC biopsies from
both male and female patients aged between 47 years and
83 years (mean age = 65 +/- 11 years; median = 67 years)
at the time of diagnosis. In order to gain an understanding
of the most common types of BCC, we elected to include
a range of BCC sub-types in this study, rather than to focus
on any particular sub-type. For this reason, BCC sub-clas-
sifications included were nodular/micronodular, superfi-
cial and sclerosing. Tissue specimens from these twenty
cases of BCC were procured at Blackrock Clinic and the
Bons Secours Hospital, Dublin, examined macroscopi-
cally, immediately snap-frozen in liquid nitrogen, and
were subsequently stored at -80°C until required for anal-
ysis. Five normal skin specimens (from consenting male
and female volunteers of a similar age range who do not/
never had skin cancer) were also included in these studies.
RNA Extraction
For RNA analyses, dissected tumours that had been snap-
frozen in liquid nitrogen and then stored at -80°C until
required were homogenised, on ice, in 1 ml TriReagent
(Sigma; Poole, England) and total RNA was subsequently
isolated according to the manufacturer's instructions.
RNA quantity and purity were assessed at 260 nm and 280
nm using a Nanodrop (ND-1000; Labtech. International);
an Agilent bioanalyser (Agilent 2100; Agilent Technolo-
gies) was used to assess RNA qualitatively after isolation
and, subsequently, after biotin-labelling and after frag-
mentation.
100 ng of each specimen was amplified and labelled using
the Affymetrix GeneChip Eukaryotic 2 Cycle Labelling
Assays for Expression Analysis, (Affymetrix; 900494)
according to the manufacturer's instructions http://
www.affymetrix.com/products/reagents/specific/
cdna2.affx. Gene expression was examined using whole
genome microarrays (Affymetrix; U133 Plus 2.0;
900470).
Microarray hybridization
Hybridisation solution (1 mol/l NaCl, 20 mmol/1 EDTA,
100 mmol/1 2-(N-morpholino) ethanesulfonic acid, and
0.01% Tween 20) was used to pre-hybridise Affymetrix;
U133 Plus 2.0 oligonucleotide microarrays for 10 minutes
at 45°C and 60 rpm. The pre-hybridisation solution was
removed and replaced with 200 µl hybridisation solution
containing 0.05 µg/µl fragmented cRNA. The arrays were
hybridised for 16 hours at 45°C and 60 rpm. Arrays were
subsequently washed (Affymetrix Fluidics Station 400)
and stained with streptavidin-phycoerythrin (Stain Buffer,
2 mg/ml acetylated BSA and 10 µg/ml streptavidin R-phy-
coerythrin; Molecular Probes, Inc., Eugene, OR), and were
scanned on an Affymetrix GCS GeneChip GeneArray scan-
ner. Resulting data was analysed using GCOS, dCHIP, and
GeneSpring (Agilent Technologies).
Normalisation and Filtering
Cel files obtained from the GCOS server were processed
and normalized by dCHIP [67] algorithm. In this normal-
isation procedure, an array with median overall intensity
is chosen as the baseline array against which other arrays
are normalized at probe intensity level. Subsequently, a
subset of PM probes, with small within-subset rank differ-
ence in the two arrays, serves as the basis for fitting a nor-
malization curve. A filter was designed to include a fold
change of at least 1.2 fold between normal and BCC spec-
imens, a difference of at least 100 Affymetrix arbitrary
units between normal and BCC average values, and a t-test
between normal and BCC (with a p-value cut-off <0.05).
Gene Ontology and Pathway Analysis Analysis
In order to establish which gene ontologies (GO) are over-
represented in our lists of 2,108 significantly up-regulated
and 1,813 significantly down-regulated (in BCCs com-
pared to normal skin) transcripts, we compared these to
the list of all human genes from the EBI [68], using Gostat
[69]. In brief, for all of the gene transcripts analysed, GOs-
tat determines the associated annotated GO terms and all
branches/splits on their connection path. The program
then counts the number of appearances of each GO term
for the gene transcripts in the list being analysed, as well
as in the reference list. For each GO term, a Chi-squared p-
value is calculated representing the probability that the
observed numbers of counts could have resulted from
randomly distributing this GO term between the tested
and the reference lists. If the expected value for any analy-
sis is <5, the Chi-squared approximation is considered to
be inaccurate. Genmapp [70] was used to identify path-
ways affected by the differentially-expressed genelist.
Real-time PCR (qPCR)
Following priming with oligo (dT) at 65°C for 5 minutes,
followed by 1 minute incubation on ice, cDNA was syn-
thesised from 100 ng total RNA, using Superscript III
RNase H- (with increased thermal stability; Invitrogen),
RNase OUT Ribonuclease (active against RNase A, B and
C; Invitrogen) and a cocktail of dNTPs, by incubating at
50°C for 1 hour, followed by 70°C for 15 minutes, in a
40  µl reaction volume. The cDNA (diluted 1:10), was
amplified in 25 µl reactions, by qPCR, using an ABI 7500
Real-Time PCR System (Applied Biosystems, Foster City,
CA). Following evaluation of 11 potential endogenous
controls in a random selection* of 4 BCC and 4 normal
specimens, this study involved evaluation, in all 20 BCCMolecular Cancer 2006, 5:74 http://www.molecular-cancer.com/content/5/1/74
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and 5 normal skin specimens, of 5 target transcripts nor-
malised to 2 suitable endogenous controls – β-actin and
GAPDH – and calibrated against a pooled cDNA of BCC
and normal skin specimens, the relative quantity of which
was set to 1. The temperature profile of all reactions was
50°C for 2 minutes 95°C for 10 minutes, 40 cycles of
95°C and 60°C for 1 minute. Individual specimens were
analysed in triplicate. [* Note: these 4 BCC and normal
specimens were analysed by microarrays with all of the
other specimens included in this study].
Abbreviations
BCC – basal cell carcinoma; qPCR – quantitative-
polymerase chain reaction
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